H.C. Wainwright raises Palvella Therapeutics stock price target to $270
Corroborated by 1 source from 1 publisher
globalbusiness8h ago
TL;DR
H.C. Wainwright reiterates Prothena stock rating on Parkinson’s data H.C. Wainwright reiterates Buy on Pyxis Oncology stock, $7 target.
Sources
1
Investing.com News
https://www.investing.com/news/analyst-ratings/hc-wainwright-reiterates-prothena-stock-rating-on-parkinsons-data-93CH-4577252
12h ago
2
Investing.com News
https://www.investing.com/news/analyst-ratings/hc-wainwright-reiterates-buy-on-pyxis-oncology-stock-7-target-93CH-4577251
12h ago
3
Investing.com News
https://www.investing.com/news/analyst-ratings/hc-wainwright-raises-palvella-therapeutics-stock-price-target-to-270-93CH-4578069
8h ago